Focus on acetylation: The role of histone deacetylase inhibitors in cancer therapy and beyond

Expert Opinion on Investigational Drugs

Volumn 16, Issue 5, 2007, Pages 569-571

  Konstantinopoulos, Panagiotis A ^a,b   Karamouzis, Michalis V ^a   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Acetylation; HAT; HDAC; HDAC inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CHAPERONE; CYTOSKELETON PROTEIN; DNA; FR 901228; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; THEOPHYLLINE; TRANSCRIPTION FACTOR; VORINOSTAT;

ACETYLATION; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHMA; CANCER; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CARDIOTOXICITY; CELL CYCLE ARREST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DEGENERATIVE DISEASE; DNA REPLICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; EDITORIAL; ENZYME INHIBITION; EPIGENETICS; FATIGUE; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATORY DISEASE; MOLECULAR MECHANICS; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PROTEIN FUNCTION; PSORIASIS; SOLID TUMOR;

ACETYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 34248190854     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.5.569     Document Type: Editorial

References (18)

1. RASHEED WK, JOHNSTONE RW, PRINCE HM: Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs (2007) 16(5):659-678.
2. KONSTANTINOPOULOS PA, PAPAVASSILIOU AG: Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol. Sci. (2007) 28(1):6-13.
3. MINUCCI S, NERVI C, LO COCO F, PELICCI PG: Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene (2001) 20(24):3110-3115.
4. PASQUALUCCI L, BERESCHENKO O, NIU H et al.: Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk. Lymphoma (2003) 44(Suppl. 3):S5-S12.
5. BOLDEN JE, PEART MJ, JOHNSTONE RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. (2006) 5(9):769-784.
6. FRAGA MF, BALLESTAR E, VILLAR-GAREA A et al.: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. (2005) 37(4):391-400.
7. INSINGA A, MONESTIROLI S, RONZONI S et al.: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. (2005) 11(1):71-76.
8. NEBBIOSO A, CLARKE N, VOLTZ E et al.: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. (2005) 11(1):77-84.
9. ZHANG K, DENT SY: Histone modifying enzymes and cancer: going beyond histories. J. Cell. Biochem. (2005) 96(6):1137-1148.
10. KONSTANTINOPOULOS PA, VANDOROS GP, PAPAVASSILIOU AG: FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother. Pharmacol. (2006) 58(5):711-715.
11. KONSTANTINOPOULOS PA, PAPAVASSILIOU AG: 17-AAG: mechanisms of antitumour activity. Expert Opin. Investig. Drugs (2005) 14(12):1471-1474.
12. BUDILLON A, BRUZZESE F, DI GENNARO E, CARAGLIA M: Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr. Drug Targets (2005) 6(3):337-351.
13. SAHA RN, PAHAN K: HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ. (2006) 13(4):539-550.
14. SADRI-VAKILI G, CHA JH: Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr. Alzheimer Res. (2006) 3(4):403-408.
15. MCLAUGHLIN F, LA THANGUE NB: Histone deacetylase inhibitors in psoriasis therapy. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):213-219.
16. REDDY P, MAEDA Y, HOTARY K et al.: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. USA (2004) 101(11):3921-3926.
17. BARNES PJ: Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac Soc. (2005) 2(4):334-339.
18. KARAGIANNIS TC, EL-OSTA A: Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia (2007) 21(1):61-65.